The economic proposition of disease-modifying therapies represents a fundamental shift from the traditional cost-accumulation model of chronic kidney disease management to an investment model ...

First non-immunosuppressive dual-action therapy approved for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

Early diagnosis and intervention create a return on investment model where up-front costs for screening, diagnosis, and early treatment yield substantial downstream cost savings while ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

1 Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China 2 Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital ...

BHV-1400, a first-in-class TRAP degrader, achieved up to 81% reduction in galactose-deficient IgA1 (Gd-IgA1), the key driver of IgA nephropathy (IgAN), after a single subcutaneous dose ...

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy ...

The company’s Biologics License Application targeting U.S. marketing approval of sibeprenlimab for IgA nephropathy is currently under FDA priority review with a target action date of Nov. 28, 2025.

A SPANISH research team has developed a non-invasive, urine-based biomarker model that accurately predicts the degree of tubulointerstitial fibrosis in patients with primary IgA nephropathy (IgAN), ...

VIENNA, June 4, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease ...